Sanofi SA (SNY) Sees Large Decrease in Short Interest
Sanofi SA (NYSE:SNY) was the target of a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 2,686,061 shares, a drop of 41.0% from the July 31st total of 4,554,476 shares. Based on an average daily trading volume, of 2,948,611 shares, the days-to-cover ratio is currently 0.9 days.
In other news, major shareholder Sanofi sold 104,552 shares of the firm’s stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.00% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Private Capital Group LLC increased its position in shares of Sanofi by 271.3% during the 1st quarter. Private Capital Group LLC now owns 2,577 shares of the company’s stock valued at $103,000 after purchasing an additional 1,883 shares during the last quarter. Whittier Trust Co. increased its position in shares of Sanofi by 290.0% during the 1st quarter. Whittier Trust Co. now owns 3,362 shares of the company’s stock valued at $135,000 after purchasing an additional 2,500 shares during the last quarter. Bray Capital Advisors bought a new position in shares of Sanofi during the 1st quarter valued at approximately $155,000. IHT Wealth Management LLC increased its position in shares of Sanofi by 246.6% during the 1st quarter. IHT Wealth Management LLC now owns 4,239 shares of the company’s stock valued at $167,000 after purchasing an additional 3,016 shares during the last quarter. Finally, Squar Milner Financial Services LLC bought a new position in shares of Sanofi during the 2nd quarter valued at approximately $169,000. 7.54% of the stock is currently owned by hedge funds and other institutional investors.
Sanofi (NYSE:SNY) last released its quarterly earnings data on Tuesday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.72 by $0.02. Sanofi had a return on equity of 23.77% and a net margin of 10.29%. The business had revenue of $8.18 billion for the quarter, compared to the consensus estimate of $8.27 billion. During the same quarter in the previous year, the company posted $1.35 EPS. The company’s revenue was down 5.6% compared to the same quarter last year. analysts anticipate that Sanofi will post 3.14 EPS for the current year.
Several equities research analysts recently commented on the company. Citigroup upgraded Sanofi from a “neutral” rating to a “buy” rating in a report on Friday, August 10th. Bank of America upgraded Sanofi from a “neutral” rating to a “buy” rating and set a $55.00 price target for the company in a research note on Monday, September 10th. ValuEngine downgraded Sanofi from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 2nd. Zacks Investment Research upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Wednesday, June 13th. Finally, Deutsche Bank reaffirmed a “buy” rating on shares of Sanofi in a research report on Wednesday, August 1st. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $49.00.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
See Also: What is the NASDAQ Stock Market?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.